For decades, the healthcare system was built around one moment: illness. Hospitals, health plans, laboratories and pharmaceutical companies have organized themselves to capture value at the point of crisis — when the patient is already sick and has no alternative but to pay. This model is so ingrained that the word "healthcare" in English contains, embedded, the assumption that there is something to be treated. What is happening now is a slow but irreversible inversion: value is migrating to before the illness, and whoever positions infrastructure at this capture point will redefine who dominates the sector.
What has changed in the economic equation of health
The logic of sick care is, in essence, reactive. It works well for the provider because demand is inelastic — no one negotiates the price of emergency heart surgery. But it's a rising cost model for those who pay the bill: employers, health plans and governments. In the United States, health spending already represents almost 18% of GDP, and a large part of this value goes to chronic conditions that are manageable — and often preventable — with early intervention.
When payers begin to understand this, the incentive changes. Health plans that manage to keep their beneficiary base healthier for longer have lower claims costs. Employers who reduce absenteeism and sick leave experience measurable productivity gains. Governments that prevent avoidable hospitalizations save scarce resources. This realignment of incentives is what opens up space for entirely new business models — and for companies that didn't exist in the traditional healthcare sector.
Wearables, biomarkers and the new raw material
What made preventative healthcare economically viable as a business model was not a shift in cultural values — it was the falling cost of collecting ongoing biometric data. An Apple Watch or Whoop measures heart rate, heart rate variability, blood oxygenation and sleep patterns in real time, over days and weeks. Continuous glucose monitoring devices, once restricted to insulin-dependent diabetics, are now used by healthy people who want to understand how different foods affect their metabolism.
US-based company Levels has built an entire business around continuous glucose monitoring for non-diabetic users. Function Health offers access to more than a hundred laboratory tests annually for a monthly subscription — the equivalent of a personalized preventive health service. Hims & Hers has built a digital health platform that includes everything from supplementation to remote prescription, all under a subscription model. The common denominator is that none of these companies exist under the sick-care model. They were built from the ground up to capture value across the wellness continuum.
In Brazil, the trajectory is similar but with lags and local specificities. Companies like Zenklub, Vitta and Nilo Saúde have built models focused on prevention and longitudinal care, exploring the gap between the traditional health plan — which covers crisis, not continuity — and what a user concerned about long-term health really needs.
Longevity clinics and the premium prevention market
The most telling segment of the transformation is longevity clinics — centers that offer intensive health assessment protocols, supervised biohacking, and precision medicine to those who can afford it. Human Longevity Inc., founded by researcher Craig Venter, sequences genomes and cross-references the data with biomarkers to generate risk reports decades in advance. Fountain Life offers what it calls "total health diagnostics" for prices starting in the tens of thousands of dollars.
This premium market is where innovations enter before becoming democratized. Hormone replacement therapies, NAD+ supplementation, whole-body MRI scans and gut microbiome tracking were niches for billionaires five years ago. Today they are being integrated into the corporate plans of large technology companies in the USA. In less than a decade, part of this preventive stack will be available at affordable prices — the same path that genetic sequencing took from $100 million to less than $200 in two decades.
How a leader should look at this
For leaders in healthcare, insurance or technology, entry into the prevention market is no longer the question — the question is where in the value chain your company has a real advantage. This market has at least three distinct layers: data collection (wearables, exams, sensors), interpretation (algorithms, medical AI, advice) and intervention (supplements, medicines, behavior, environment). These tiers have very different competitive dynamics.
Health plans that still resist covering regular preventive consultations are, in practice, transferring the cost of their inefficiencies to employers and the public system. Employers who realized this first are building corporate health programs with measurable ROI: reduced lost days, decreased plan expenses per beneficiary, increased productivity. This is the argument that breaks down the CFO's resistance — not the feel-good narrative, but the avoided cost spreadsheet.
For startups, the clearest opportunity lies in continuity gaps — the spaces between traditional healthcare system touchpoints. The doctor sees the patient once a year. The health plan only appears at the time of the crisis. Between those two points, there are 364 days of data, behaviors, and microinterventions that no one is capturing or monetizing. Whoever builds infrastructure in these interstices will have bargaining power that no hospital or traditional plan will have.
Also read
- The longevity market and what it reveals about the future of health plans
- Corporate wearables: when health data becomes a strategic asset for companies
- Post-smartphone interfaces: what comes after the screen in the palm of your hand
- Smart glasses and augmented reality: real promise and concrete barriers
- Distributed solar energy and the business model that emerged around it
- The days of the attention business model are numbered